lutetium Lu 177 vipivotide tetraxetan
FDA Expands Pluvicto’s Metastatic Castration-Resistant Prostate Cancer Indication
The FDA expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) to include adults ...
APRIL 2, 2025
Targeted Radioligand Therapy Approved to Treat Advanced Prostate Cancer
The FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis), a targeted radioligand therapy, for ...
MARCH 25, 2022
Load more